Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.
Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.
复制标题
基于细胞的急性器官损伤治疗：使用间充质干细胞进行的临床前证据和正在进行的临床试验。
DOI：
10.1097/aln.0000000000000446
复制
发表时间：
2014-11
期刊：
影响因子：
8.8
通讯作者：
Lee JW
中科院分区：
文献类型：
--
作者：
Monsel A;Zhu YG;Gennai S;Hao Q;Liu J;Lee JW
重症患者通常患有涉及肺、肾、肝或脑的多器官衰竭。基因组学、蛋白质组学和代谢组学方法突出了导致急性器官衰竭的常见损伤机制。这强调了需要关注影响多个损伤途径的治疗策略。成体干细胞如间充质干细胞或基质细胞（MSC）的使用可能代表一种有前途的新治疗方法，因为越来越多的证据表明MSC可以通过释放促有丝分裂、抗凋亡、抗炎和免疫调节可溶性因子在损伤后发挥保护作用。此外，它们可以减轻代谢组学和氧化应激失衡。在这项工作中，我们回顾了MSC的生物学能力和临床试验的结果，使用MSC治疗急性器官损伤。虽然初步结果令人鼓舞，但需要更多关于MSC治疗的安全性和有效性的研究，以确定其最佳临床用途。
Critically ill patients often suffer from multiple organ failures involving lung, kidney, liver or brain. Genomic, proteomic and metabolomic approaches highlight common injury mechanisms leading to acute organ failure. This underlines the need to focus on therapeutic strategies affecting multiple injury pathways. The use of adult stem cells such as mesenchymal stem or stromal cells (MSC) may represent a promising new therapeutic approach as increasing evidence shows that MSC can exert protective effects following injury through the release of pro-mitotic, anti-apoptotic, anti-inflammatory and immunomodulatory soluble factors. Furthermore, they can mitigate metabolomic and oxidative stress imbalance. In this work, we review the biological capabilities of MSC and the results of clinical trials using MSC as therapy in acute organ injuries. Although preliminary results are encouraging, more studies concerning safety and efficacy of MSC therapy are needed to determine their optimal clinical use.